Market Spotlight: Obesity
Market Spotlight: Obesity
$1,318.00
This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were approximately 681.3 million prevalent cases of obesity in adults (aged 20+ years) worldwide, and expects that number to increase to 762.9 million prevalent cases by 2026.
- In the same year, Datamonitor Healthcare estimates that there were 126.6 million prevalent cases of obesity in children and adolescents (aged 5–19 years) worldwide, and expects that number to increase to 134.0 million prevalent cases by 2026.
- Prevalence proportions are highest in Northern America and lowest in Asia. The approved drugs in the obesity space target gastric lipase, dopamine, norepinephrine (noradrenaline), dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, opioid receptors, GABA-A receptor, and glucagon-like peptide-1 (GLP-1) receptor. The majority of marketed drugs are administered via the oral route, with one product being available in a subcutaneous formulation.
- The majority of industry-sponsored drugs in active clinical development for obesity are in Phase I, with two drugs in Phase III. Therapies in development for obesity focus on a wide variety of targets, with the subcutaneous route being the most common method of delivery.
- High-impact upcoming events for drugs in the obesity space comprise an expected PDUFA date, a decentralized EU approval, and an estimated EU patent expiration for Qsymia; topline Phase II trial results for AM833; and topline Phase III trial results for Ozempic.
- The overall likelihood of approval of a Phase I obesity asset is 2.5%, and the average probability a drug advances from Phase III is 62.5%. Drugs, on average, take 8.5 years from Phase I to approval, compared to 8.9 years in the overall metabolic space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for obesity have been in the early and midphases of development, with 66% of trials in Phase I–II, and 34% in Phase III–IV.
- The US has a substantial lead in the number of obesity clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the obesity space is dominated by completed trials. AstraZeneca has the highest number of completed clinical trials for obesity, with 77 trials.
- Novo Nordisk leads industry sponsors with the highest overall number of clinical trials for obesity, followed by AstraZeneca.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Medications
9 Surgery
11 EPIDEMIOLOGY
17 MARKETED DRUGS
19 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 Tesomet for Obesity (April 22, 2020)
27 Efpeglenatide for Obesity (December 10, 2019)
28 HM12525A for Obesity (July 3, 2019)
29 NS-0200 for Obesity (June 8, 2019)
31 PLENITY for Obesity (April 14, 2019)
32 PLENITY for Obesity (March 25, 2019)
35 Qsymia for Obesity (January 15, 2019)
36 Lap-Band System for Obesity (December 17, 2018)
38 Obalon Balloon System for Obesity (November 15, 2018)
39 TransPyloric Shuttle for Obesity (November 14, 2018)
41 Obalon Balloon System for Obesity (November 13, 2018)
42 PLENITY for Obesity (November 13, 2018)
44 KEY UPCOMING EVENTS
45 KEY REGULATORY EVENTS
45 EMA Considers Fast-Tracking Rhythm’s Insatiable Hunger and Obesity Disorders Drug
45 Three Fast Track Drugs Stand Out In Flurry Of Submissions
45 FDA Requests Belviq Be Pulled From The US Market Due To Cancer Risk
45 Preparing For Qsymia Launch In Korea
47 PROBABILITY OF SUCCESS
48 LICENSING AND ASSET ACQUISITION DEALS
48 Novo/Fauna Partnership Includes Options To Resulting Drug Candidates
48 Novo Nordisk Enters Its First Strategic RNAi Pact
48 Numaferm And Polpharma Sign Deals
48 BI Inks Second Obesity Pact With Denmark’s Gubra
50 REVENUE OPPORTUNITY
51 CLINICAL TRIAL LANDSCAPE
52 Sponsors by status
53 Sponsors by phase
54 Recent events
56 BIBLIOGRAPHY
56 Prescription information
57 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of obesity in adults, 2017–26
19 Figure 2: Overview of pipeline drugs for obesity in the US
19 Figure 3: Pipeline drugs for obesity, by company
20 Figure 4: Pipeline drugs for obesity, by drug type
20 Figure 5: Pipeline drugs for obesity, by classification
27 Figure 6: Tesomet for Obesity (April 22, 2020): Phase IIa – Hypothalamic Obesity (Denmark)
31 Figure 7: NS-0200 for Obesity (June 8, 2019): Phase II – NS-WM-01
41 Figure 8: TransPyloric Shuttle for Obesity (November 14, 2018): ENDObesity II (US)
43 Figure 9: PLENITY for Obesity (November 13, 2018): Phase II – GLOW (EU & US)
44 Figure 10: Key upcoming events in obesity
47 Figure 11: Probability of success in the obesity pipeline
51 Figure 12: Clinical trials in obesity
51 Figure 13: Top 10 drugs for clinical trials in obesity
52 Figure 14: Top 10 companies for clinical trials in obesity
52 Figure 15: Trial locations in obesity
53 Figure 16: Obesity trials status
54 Figure 17: Obesity trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of obesity in adults, 2017–26
14 Table 2: Prevalent cases of morbid obesity in adults, 2017–26
15 Table 3: Prevalent cases of obesity in children and adolescents, 2017–26
16 Table 4: Prevalence proportions of obesity and morbid obesity, 2017
18 Table 5: Marketed drugs for obesity
21 Table 6: Pipeline drugs for obesity in the US
26 Table 7: Tesomet for Obesity (April 22, 2020)
28 Table 8: Efpeglenatide for Obesity (December 10, 2019)
29 Table 9: HM12525A for Obesity (July 3, 2019)
30 Table 10: NS-0200 for Obesity (June 8, 2019)
31 Table 11: PLENITY for Obesity (April 14, 2019)
33 Table 12: PLENITY for Obesity (March 25, 2019)
35 Table 13: Qsymia for Obesity (January 15, 2019)
36 Table 14: Lap-Band System for Obesity (December 17, 2018)
39 Table 15: Obalon Balloon System for Obesity (November 15, 2018)
40 Table 16: TransPyloric Shuttle for Obesity (November 14, 2018)
41 Table 17: Obalon Balloon System for Obesity (November 13, 2018)
42 Table 18: PLENITY for Obesity (November 13, 2018)
50 Table 19: Historical global sales, by drug ($m), 2014–18
50 Table 20: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Hereditary Angioedema 
Sign up to the